CI: 22–47 percent). It was encouraging that RTS,S also showed significant protection against severe malaria in children, estimated at 58 percent (95 percent CI: 16–81 percent) in the first six months and 49 percent (95 percent CI: 12–71 percent) over an 18 month period (Alonso et al., 2004, 2005). No significant safety issue associated with RTS,S vaccines was found, although the frequency of some local and systemic adverse effects (e.g., injection site pain, malaise) was increased compared to placebo (Bojang et al., 2005). Protection was not limited to the CSP variants used to make the vaccine (Alloueche et al., 2003).

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement